This content is machine translated Plaque psoriasis New “Real World” Study on Tildrakizumab In a retrospective study of 30 patients with moderate to severe plaque psoriasis, the use of the IL-23 inhibitor tildrakizumab was shown to be effective and safe in clinical practice.…
